Diarrhea The second most common side effect, affecting a higher percentage of participants at higher doses
Stimulating GLP-1R in BMSCs triggers the buildup of nuclear -catenin, which, in turn, activates osteogenic genes by binding with TCF7L12
Pregnancy and breastfeeding : Retatrutide is not recommended during pregnancy or breastfeeding, as its safety in these situations has not been established
Self-directed dose adjustments can compromise treatment outcomes and patient safety
Once the solution is clear, store it in the refrigerator and use within 28 days
According to standard clinical guidance and Omzo's own eligibility framing, licensed clinicians evaluating GLP-1 candidacy typically consider factors like body mass index, medical history, existing conditions (particularly thyroid disease, pancreatitis, or other contraindications for GLP-1 medications), current medications, and personal health goals